Le Lézard
Classified in: Health

Barlow Respiratory Hospital Completes Re-Certification Review


LOS ANGELES, April 19, 2018 /PRNewswire/ -- Barlow Respiratory Hospital announces the conclusion of an in-depth recertification review by the Joint Commission to maintain Disease Specific Certification for Respiratory Failure.

Barlow Respiratory Hospital Logo

The certification is a symbol of clinical expertise and quality that reflects an organization's commitment to providing safe and effective patient care at each of the hospital's three locations in the Los Angeles metropolitan area. Barlow is the first and only health care organization in California to achieve this certification and among only nineteen in the nation.

Barlow Respiratory Hospital initially underwent a rigorous on-site review in March 2016 and again in April 2018. The Joint Commission evaluated compliance with national disease-specific care standards and clinical practice and performance improvement at all three Barlow sites (Los Angeles, Van Nuys and Whittier, California.)

"Our team is dedicated to the work of transforming the lives of patients. Renewal of this certification validates our culture of excellence in the care of patients with complex respiratory conditions."
Amit Mohan, PhD
Barlow Respiratory Hospital CEO

Barlow's interdisciplinary care teams include board certified pulmonologists and internists, registered nurses, respiratory therapists, licensed social workers, physical and occupational therapists, speech-language pathologists, case managers and dietitians.

The hospital's TIPS© Protocol for Ventilator Weaning has proven to be so successful in weaning patients from mechanical ventilation that doctors from the finest hospitals in Los Angeles regularly refer their patients to Barlow for post-ICU (Intensive Care Unit) treatment. Barlow Respiratory Hospital specializes in treating the chronically critically ill and patients with complex respiratory conditions. Weaning patients from the ventilator to breathe on their own again is central to the hospital's mission and helps patients return to their lives and to their loved ones.

About Barlow Respiratory Hospital: Barlow is the only not-for-profit respiratory hospital in Los Angeles and is recognized for excellence in treating patients dependent on a ventilator to breathe. Barlow is also the only West Coast Passy-Muir Center of Excellence, recognized for treating patients with tracheostomies, on and off the ventilator. Visit us online to learn more about Barlow Respiratory Hospital.

Contact:  (213) 202-6832, [email protected], www.barlowhospital.org

 

SOURCE Barlow Respiratory Hospital


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: